These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 23184667

  • 1. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [Abstract] [Full Text] [Related]

  • 2. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K.
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [Abstract] [Full Text] [Related]

  • 3. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y, Zeng JC, Yin F, Zhang CL, Zhang Y, Li SX, Liu X, Zhang C, Xue QY, Lin H, Pei FX.
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [Abstract] [Full Text] [Related]

  • 4. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
    Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E.
    Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
    [Abstract] [Full Text] [Related]

  • 5. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 6. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W, Emkey R, Civitelli R.
    Drug Saf; 2007 Jul; 30(9):755-63. PubMed ID: 17722968
    [Abstract] [Full Text] [Related]

  • 7. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.
    Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J, Mesenbrink P, de Villiers TJ.
    Osteoporos Int; 2012 Feb; 23(2):503-12. PubMed ID: 21331467
    [Abstract] [Full Text] [Related]

  • 8. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
    Crotti C, Watts NB, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F, Marasini B, Selmi C, Massarotti M.
    Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
    [Abstract] [Full Text] [Related]

  • 9. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
    Dalle Carbonare L, Bertoldo F, Lo Cascio V.
    Reumatismo; 2009 May; 61(1):54-64. PubMed ID: 19370189
    [Abstract] [Full Text] [Related]

  • 10. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.
    Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
    [Abstract] [Full Text] [Related]

  • 11. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
    Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group.
    J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
    [Abstract] [Full Text] [Related]

  • 12. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD.
    Drug Saf; 2006 Jan; 29(12):1133-52. PubMed ID: 17147460
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG, Stavropoulos MF, Bowers LM, Neuman AN, Hinkson DW, Green JG, Bhattacharyya I, Cohen DM.
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract] [Full Text] [Related]

  • 14. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.
    Katz J, Ordoveza PA.
    Quintessence Int; 2014 Sep; 45(8):685-90. PubMed ID: 25019116
    [Abstract] [Full Text] [Related]

  • 16. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
    Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E.
    Quintessence Int; 2016 Sep; 47(5):433-40. PubMed ID: 26665262
    [Abstract] [Full Text] [Related]

  • 17. Intravenous zoledronic acid for the treatment of osteoporosis.
    Lewiecki EM.
    Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
    [Abstract] [Full Text] [Related]

  • 18. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
    Lambrinoudaki I, Vlachou S, Galapi F, Papadimitriou D, Papadias K.
    Clin Interv Aging; 2008 Mar; 3(3):445-51. PubMed ID: 18982915
    [Abstract] [Full Text] [Related]

  • 19. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
    Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N.
    Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
    [Abstract] [Full Text] [Related]

  • 20. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG.
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.